OBJECTIVE: To investigate the incidence of, and risk factors for, tuberculosis among HIV clinic attendees in the United Kingdom. DESIGN AND METHODS: Observational cohort study of 27 868 individuals in the United Kingdom Collaborative HIV Cohort collaboration, 1996-2005. RESULTS: Among individuals not taking combination antiretroviral therapy (cART), tuberculosis incidence was considerably higher among individuals of black African vs. white or other ethnicities {incidence rates 9.9 [95% confidence intervals (CIs) 7.2, 12.6], 2.5 [95% CI 1.8, 3.0] and 4.4 [95% CI 2.7, 6.0] episodes per 1000 person-years, respectively}. Tuberculosis incidence decreased with time after starting cART; among black Africans, incidence was consistently higher and remained substantial (5.3 per 1000 person-years) at 24 months and longer after starting cART. The strongest independent risk factors for tuberculosis after cART start were most recent CD4 cell count: adjusted rate ratios (aRR) 10.65 (95% CI 6.11, 18.57), 3.40 (95% CI 2.05, 5.65), 1.77 (95% CI 1.06, 2.96) and 1.84 (95% CI 1.09, 3.12) for individuals with CD4 cell counts less than 50, 50-199, 200-349 and 350-499 cells/microl, respectively, compared with at least 500 cells/microl; and black African vs. white ethnicity [aRR 2.93 (95% CI 1.89, 4.54)]. HIV risk group, shorter time on cART, later calendar period and unsuppressed viral load were also independently associated with incident tuberculosis. CONCLUSIONS: Tuberculosis incidence among people attending UK HIV clinics is substantial, particularly among those with non-white ethnicity and low CD4 cell counts, even after starting cART. Earlier HIV diagnosis is needed in order to implement interventions to prevent tuberculosis; tuberculosis preventive therapy should be considered in addition to cART.
OBJECTIVE: To investigate the incidence of, and risk factors for, tuberculosis among HIV clinic attendees in the United Kingdom. DESIGN AND METHODS: Observational cohort study of 27 868 individuals in the United Kingdom Collaborative HIV Cohort collaboration, 1996-2005. RESULTS: Among individuals not taking combination antiretroviral therapy (cART), tuberculosis incidence was considerably higher among individuals of black African vs. white or other ethnicities {incidence rates 9.9 [95% confidence intervals (CIs) 7.2, 12.6], 2.5 [95% CI 1.8, 3.0] and 4.4 [95% CI 2.7, 6.0] episodes per 1000 person-years, respectively}. Tuberculosis incidence decreased with time after starting cART; among black Africans, incidence was consistently higher and remained substantial (5.3 per 1000 person-years) at 24 months and longer after starting cART. The strongest independent risk factors for tuberculosis after cART start were most recent CD4 cell count: adjusted rate ratios (aRR) 10.65 (95% CI 6.11, 18.57), 3.40 (95% CI 2.05, 5.65), 1.77 (95% CI 1.06, 2.96) and 1.84 (95% CI 1.09, 3.12) for individuals with CD4 cell counts less than 50, 50-199, 200-349 and 350-499 cells/microl, respectively, compared with at least 500 cells/microl; and black African vs. white ethnicity [aRR 2.93 (95% CI 1.89, 4.54)]. HIV risk group, shorter time on cART, later calendar period and unsuppressed viral load were also independently associated with incident tuberculosis. CONCLUSIONS:Tuberculosis incidence among people attending UK HIV clinics is substantial, particularly among those with non-white ethnicity and low CD4 cell counts, even after starting cART. Earlier HIV diagnosis is needed in order to implement interventions to prevent tuberculosis; tuberculosis preventive therapy should be considered in addition to cART.
Authors: Julia del Amo; Santiago Moreno; Heiner C Bucher; Hansjakob Furrer; Roger Logan; Jonathan Sterne; Santiago Pérez-Hoyos; Inma Jarrín; Andrew Phillips; Sara Lodi; Ard van Sighem; Wolf de Wolf; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; José M Miró; Elena Ferrer; Laurence Meyer; Rémonie Seng; Giota Toulomi; Panagiotis Gargalianos; Dominique Costagliola; Sophie Abgrall; Miguel A Hernán Journal: Clin Infect Dis Date: 2012-03-28 Impact factor: 9.079
Authors: Bryan E Shepherd; Cathy A Jenkins; Deidra D Parrish; Tracy R Glass; Angela Cescon; Angels Masabeu; Genevieve Chene; Frank de Wolf; Heidi M Crane; Inma Jarrin; John Gill; Julia del Amo; Sophie Abgrall; Pavel Khaykin; Clara Lehmann; Suzanne M Ingle; Margaret T May; Jonathan A C Sterne; Timothy R Sterling Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Ziemlé Clément Méda; Issiaka Sombié; Olivier W C Sanon; Daouda Maré; Donald E Morisky; Yi-Ming Arthur Chen Journal: AIDS Res Hum Retroviruses Date: 2013-05-09 Impact factor: 2.205
Authors: Meaghan M Kall; Katherine M Coyne; Nigel J Garrett; Aileen E Boyd; Anthony T Ashcroft; Iain Reeves; Jane Anderson; Graham H Bothamley Journal: BMC Infect Dis Date: 2012-05-04 Impact factor: 3.090
Authors: Graham H Bothamley; Michelle E Kruijshaar; Heinke Kunst; Gerrit Woltmann; Mark Cotton; Dinesh Saralaya; Mark A Woodhead; John P Watson; Ann L N Chapman Journal: BMC Public Health Date: 2011-11-28 Impact factor: 3.295
Authors: Katrina M Pollock; Herman Tam; Lisa Grass; Sharleen Bowes; Graham S Cooke; Manish Pareek; Damien Montamat-Sicotte; Moses Kapembwa; Graham P Taylor; Ajit Lalvani Journal: BMJ Open Date: 2012-03-01 Impact factor: 2.692
Authors: Baba Maiyaki Musa; Babashani Musa; Hamza Muhammed; Nashabaru Ibrahim; Abubakar Garbati Musa Journal: Ann Thorac Med Date: 2015 Jul-Sep Impact factor: 2.219